Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes

Tekatli, H.; Senan, Suresh; Dahele, Max; Slotman, Ben J.; Verbakel, Wilko F.A.R.

doi:10.1016/j.radonc.2015.09.028

Cited by 55 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the dose constraints of the esophagus in this study (V 40Gy < 1cc), for example, may be conservative because Stephans et al reported that no esophageal fistula was found in patients with esophageal 1-cc doses below 48 Gy [15]. At the same time, Tekatli et al reported that 1 of the 2 patients treated with 35 -40 Gy in 8 fractions at D 0.5cc of the esophagus experienced Grade 3 esophageal toxicity [16]. The esophageal dose constraint in our study seems to be biologically higher than a D 0.5cc equal to 40 Gy 16 considering the fractionation number.…”

Section: Discussionmentioning

confidence: 71%

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV ⩾ 100 cc

Onimaru

Oda

Shibata

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

Purpose: A dose escalation study to determine the recommended dose (RD) with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (NSCLC) was conducted. The results of the group with PTV ≥ 100 cc is reported in this paper. Materials and Methods:The continual reassessment method (CRM) was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) was Grade 3 or higher radiation pneumonitis (RP), and Grade 2 or higher RP was used as a surrogate DLT. The RD was equal to the MTD. The dose was prescribed at D 95 of the PTV.Results: Thirteen patients were accrued. More patients should have been enrolled but we decided not to prolong the study period. No patients experienced Grade 3 RP. Two patients experienced Grade 2 RP at 50 Gy in 4 fractions. The predicted MTD was 50.2Gy. The posterior probability of the Grade 2 RP frequency over 40% was 5.3% for the dose level of 50 Gy. The RD was determined to be 50 Gy.

show abstract

Section: Discussionmentioning

confidence: 71%

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV ⩾ 100 cc

Onimaru

Oda

Shibata

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Tekatli et al 84,85 report the outcomes of 80 patients with tumour PTV within 2 cm of the proximal bronchial tree and 47 patients with more ultracentral tumours, defined as the PTV in contact with the trachea or main bronchi. The patients were treated with 60 Gy/ 8# (BED for tissue with an alpha/beta ratio of 10 5 105 Gy).…”

Section: Sabr For Central Lesions In Lung Cancermentioning

confidence: 99%

A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer

Murray

Franks

Hanna

2017

The British Journal of Radiology

View full text Add to dashboard Cite

Stereotactic ablative body radiotherapy (SABR) describes a radiotherapy (RT) technique where high doses of radiation are precisely delivered to an extracranial target within the body, using either a single fraction of RT or using multiple small numbers of fractions. SABR has now become the standard of care treatment for patients with early-stage non-small-cell lung cancer (NSCLC) for whom surgery is not appropriate. This systematic review considers the evidence supporting the use of SABR in early-stage NSCLC, reported toxicity rates, the use of SABR in centrally located NSCLC, the use of SABR as salvage therapy following surgery or RT, and future potential drug combinations with SABR.

show abstract

“…We analyzed clinical data from seven patients with some of the most central tumors that we have treated with 8 fractions of 7.5 Gy (Supplementary Figure 1, available online at http:// www.informahealthcare.com) [10]. In brief, all treatment plans were generated using a free-breathing, uncoached, 10 phase four-dimensional (4D) CT scan with 2.5 mm slice thickness.…”

Section: Methodsmentioning

confidence: 99%

“…This has led to greater caution about applying it to centrally located lung tumors. These are closer to numerous organs at risk (OAR) including the trachea and proximal bronchial tree (PBT) and so the risks are higher, especially for very central tumors [4][5][6][7][8][9][10]. To better understand the risks, we evaluated whether the high-dose region delivered to the PBT wall (PBTWall) reflected the planned dose distribution when treatment was performed with on-line cone-beam computed tomography (CBCT) and positioning based on the tumor.…”

mentioning

confidence: 99%

An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes

Cited by 55 publications

References 35 publications

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV ⩾ 100 cc

Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV ⩾ 100 cc

A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer

An analysis of planned versus delivered airway doses during stereotactic lung radiotherapy for central tumors

Contact Info

Product

Resources

About